Source:http://linkedlifedata.com/resource/pubmed/id/21892283
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0079083,
umls-concept:C0205179,
umls-concept:C0210657,
umls-concept:C0332283,
umls-concept:C0521115,
umls-concept:C0543467,
umls-concept:C0546837,
umls-concept:C0600688,
umls-concept:C0851346,
umls-concept:C0936012,
umls-concept:C1274040,
umls-concept:C1301732,
umls-concept:C1517927,
umls-concept:C1518419,
umls-concept:C2603343,
umls-concept:C2827738
|
pubmed:dateCreated |
2011-9-5
|
pubmed:abstractText |
This brief report describes a planned, interim, 6-patient toxicity analysis that confirms the safety of pemetrexed, carboplatin, radiation with subsequent surgery, as prescribed in the North Central Cancer Treatment Group trial N044E, in patients with locally advanced esophageal cancer.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:status |
PubMed-not-MEDLINE
|
pubmed:issn |
1177-9314
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
2
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
223-5
|
pubmed:year |
2008
|
pubmed:articleTitle |
Pemetrexed, Carboplatin, and Concomitant Radiation followed by Surgery for Locally Advanced Esophageal Cancer: Results of a Planned Interim Toxicity Analysis of North Central Cancer Treatment Group Study N044E.
|
pubmed:affiliation |
Department of Oncology, Mayo Clinic, Rochester, Minnesota.
|
pubmed:publicationType |
Journal Article
|